Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ia/Ib, Randomized, Double Blinded, Dose Escalation Trial to Evaluate the Safety and Immunogenicity in Healthy European and Burkinabe Adults of a Placental Malaria Vaccine Candidate (PRIMVAC) Formulated With Alhydrogel ® or GLA-SE

NCT02658253 is registered in ClinicalTrials.gov with Institut National de la Santé Et de la Recherche Médicale, France as lead sponsor.

NCT NCT02658253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02658253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ia/Ib, Randomized, Double Blinded, Dose Escalation Trial to Evaluate the Safety and Immunogenicity in Healthy European and Burkinabe Adults of a Placental Malaria Vaccine Candidate (PRIMVAC) Formulated With Alhydrogel ® or GLA-SE
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2016
Completion date
February 21, 2019
Enrollment
68 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malaria